Cargando…
The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats
The distribution, clearance, and bioavailability of (2S,6S)-hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)-hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)-hydroxynork...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492732/ https://www.ncbi.nlm.nih.gov/pubmed/26171236 http://dx.doi.org/10.1002/prp2.157 |
_version_ | 1782379809511309312 |
---|---|
author | Moaddel, Ruin Sanghvi, Mitesh Dossou, Katina Sourou Sylvestre Ramamoorthy, Anuradha Green, Carol Bupp, James Swezey, Robert O’Loughlin, Kathleen Wainer, Irving W |
author_facet | Moaddel, Ruin Sanghvi, Mitesh Dossou, Katina Sourou Sylvestre Ramamoorthy, Anuradha Green, Carol Bupp, James Swezey, Robert O’Loughlin, Kathleen Wainer, Irving W |
author_sort | Moaddel, Ruin |
collection | PubMed |
description | The distribution, clearance, and bioavailability of (2S,6S)-hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)-hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)-hydroxynorketamine (n = 3). After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t(1/2)) was 8.0 ± 4.0 h and the apparent volume of distribution (V(d)) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%. Significant concentrations of (2S,6S)-hydroxynorketamine were measured in brain tissues at 10 min after intravenous administration, ∼30 μg/mL per g tissue which decreased to 6 μg/mL per g tissue at 60 min. The plasma and brain concentrations of (2S,6S)-hydroxynorketamine were also determined after the intravenous administration of (S)-ketamine, where significant plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine were observed 10 min after administration. The (S)-ketamine metabolites (S)-norketamine, (S)-dehydronorketamine, (2S,6R)-hydroxynorketamine, (2S,5S)-hydroxynorketamine and (2S,4S)-hydroxynorketamine were also detected in both plasma and brain tissue. The enantioselectivity of the conversion of (S)-ketamine and (R)-ketamine to the respective (2,6)-hydroxynorketamine metabolites was also investigated over the first 60 min after intravenous administration. (S)-Ketamine produced significantly greater plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine relative to the (2R,6R)-hydroxynorketamine observed after the administration of (R)-ketamine. However, the relative brain tissue: plasma concentrations of the enantiomeric (2,6)-hydroxynorketamine metabolites were not significantly different indicating that the penetration of the metabolite is not enantioselective. |
format | Online Article Text |
id | pubmed-4492732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44927322015-07-13 The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats Moaddel, Ruin Sanghvi, Mitesh Dossou, Katina Sourou Sylvestre Ramamoorthy, Anuradha Green, Carol Bupp, James Swezey, Robert O’Loughlin, Kathleen Wainer, Irving W Pharmacol Res Perspect Original Articles The distribution, clearance, and bioavailability of (2S,6S)-hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)-hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)-hydroxynorketamine (n = 3). After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t(1/2)) was 8.0 ± 4.0 h and the apparent volume of distribution (V(d)) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%. Significant concentrations of (2S,6S)-hydroxynorketamine were measured in brain tissues at 10 min after intravenous administration, ∼30 μg/mL per g tissue which decreased to 6 μg/mL per g tissue at 60 min. The plasma and brain concentrations of (2S,6S)-hydroxynorketamine were also determined after the intravenous administration of (S)-ketamine, where significant plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine were observed 10 min after administration. The (S)-ketamine metabolites (S)-norketamine, (S)-dehydronorketamine, (2S,6R)-hydroxynorketamine, (2S,5S)-hydroxynorketamine and (2S,4S)-hydroxynorketamine were also detected in both plasma and brain tissue. The enantioselectivity of the conversion of (S)-ketamine and (R)-ketamine to the respective (2,6)-hydroxynorketamine metabolites was also investigated over the first 60 min after intravenous administration. (S)-Ketamine produced significantly greater plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine relative to the (2R,6R)-hydroxynorketamine observed after the administration of (R)-ketamine. However, the relative brain tissue: plasma concentrations of the enantiomeric (2,6)-hydroxynorketamine metabolites were not significantly different indicating that the penetration of the metabolite is not enantioselective. John Wiley & Sons, Ltd 2015-08 2015-06-22 /pmc/articles/PMC4492732/ /pubmed/26171236 http://dx.doi.org/10.1002/prp2.157 Text en © 2015 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Moaddel, Ruin Sanghvi, Mitesh Dossou, Katina Sourou Sylvestre Ramamoorthy, Anuradha Green, Carol Bupp, James Swezey, Robert O’Loughlin, Kathleen Wainer, Irving W The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats |
title | The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats |
title_full | The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats |
title_fullStr | The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats |
title_full_unstemmed | The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats |
title_short | The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats |
title_sort | distribution and clearance of (2s,6s)-hydroxynorketamine, an active ketamine metabolite, in wistar rats |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492732/ https://www.ncbi.nlm.nih.gov/pubmed/26171236 http://dx.doi.org/10.1002/prp2.157 |
work_keys_str_mv | AT moaddelruin thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT sanghvimitesh thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT dossoukatinasourousylvestre thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT ramamoorthyanuradha thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT greencarol thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT buppjames thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT swezeyrobert thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT oloughlinkathleen thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT wainerirvingw thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT moaddelruin distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT sanghvimitesh distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT dossoukatinasourousylvestre distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT ramamoorthyanuradha distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT greencarol distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT buppjames distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT swezeyrobert distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT oloughlinkathleen distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats AT wainerirvingw distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats |